Ziprasidone mesylate
Products billed under this code include Geodon, Ziprasidone Mesylate.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Geodon, Ziprasidone Mesylate.
Payment limit per 10 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Geodon | Viatris Specialty LLC | 00049-3920-10 | 20 | $118.80 |
| Geodon | A-S Medication Solutions | 50090-4540-00 | 2 | $11.88 |
| Geodon | Viatris Specialty LLC | 58151-0137-81 | 20 | $118.80 |
| Ziprasidone Mesylate | Dr. Reddy's Laboratories Inc. | 43598-0061-58 | 20 | $118.80 |
| Ziprasidone Mesylate | Dr. Reddy's Laboratories Inc. | 43598-0848-58 | 20 | $118.80 |
| Ziprasidone Mesylate | HF Acquisition Co. LLC, DBA HealthFirst | 51662-1564-03 | 100 | $594.00 |
| Ziprasidone Mesylate | Novadoz Pharmaceuticals LLC | 72205-0205-07 | 20 | $118.80 |
| Ziprasidone Mesylate | Fosun Pharma USA Inc. | 72266-0160-10 | 20 | $118.80 |
| Ziprasidone Mesylate | Fosun Pharma USA Inc. | 72266-0160-42 | 20 | $118.80 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $5.94 | +$0.338 | 10 MG | Ziprasidone mesylate | v1, posted September 17, 2026 |
| 3Q26 | $5.602 | −$0.271 | 10 MG | Ziprasidone mesylate | v1, posted September 15, 2026 |
| 2Q26 | $5.873 | −$3.275 | 10 MG | Ziprasidone mesylate | v1, posted September 15, 2026 |
| 1Q26 | $9.148 | +$2.322 | 10 MG | Ziprasidone mesylate | v1, posted September 15, 2026 |
| 4Q25 | $6.826 | +$3.688 | 10 MG | Ziprasidone mesylate | v1, posted September 8, 2026 |
| 3Q25 | $3.138 | −$2.045 | 10 MG | Ziprasidone mesylate | v1, posted March 10, 2026 |
| 2Q25 | $5.183 | −$2.008 | 10 MG | Ziprasidone mesylate | v1, posted March 10, 2026 |
| 1Q25 | $7.191 | −$0.241 | 10 MG | Ziprasidone mesylate | v1, posted December 19, 2025 |
| 4Q24 | $7.432 | −$0.65 | 10 MG | Ziprasidone mesylate | v1, posted June 11, 2025 |
| 3Q24 | $8.082 | −$2.139 | 10 MG | Ziprasidone mesylate | v1, posted June 11, 2025 |
| 2Q24 | $10.221 | +$0.466 | 10 MG | Ziprasidone mesylate | v1, posted March 11, 2025 |
| 1Q24 | $9.755 | −$0.19 | 10 MG | Ziprasidone mesylate | v1, posted December 19, 2024 |
| 4Q23 | $9.945 | +$0.342 | 10 MG | Ziprasidone mesylate | v1, posted October 10, 2024 |
| 3Q23 | $9.603 | −$0.515 | 10 MG | Ziprasidone mesylate | v1, posted June 5, 2024 |
| 2Q23 | $10.118 | −$0.038 | 10 MG | Ziprasidone mesylate | v1, posted February 23, 2024 |
| 1Q23 | $10.156 | −$0.819 | 10 MG | Ziprasidone mesylate | v1, posted December 6, 2023 |
| 4Q22 | $10.975 | −$0.609 | 10 MG | Ziprasidone mesylate | v1, posted June 22, 2023 |
| 3Q22 | $11.584 | −$0.933 | 10 MG | Ziprasidone mesylate | v1, posted June 9, 2023 |
| 2Q22 | $12.517 | −$0.865 | 10 MG | Ziprasidone mesylate | v1, posted December 14, 2022 |
| 1Q22 | $13.382 | −$1.463 | 10 MG | Ziprasidone mesylate | v1, posted June 8, 2022 |
| 4Q21 | $14.845 | −$1.583 | 10 MG | Ziprasidone mesylate | v1, posted June 2, 2022 |
| 3Q21 | $16.428 | −$1.622 | 10 MG | Ziprasidone mesylate | v1, posted June 2, 2022 |
| 2Q21 | $18.05 | −$2.901 | 10 MG | Ziprasidone mesylate | v1, posted March 1, 2022 |
| 1Q21 | $20.951 | – | 10 MG | Ziprasidone mesylate | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.